Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) COO Sells 4,500 Shares of Stock

BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu sold 4,500 shares of the company’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $200.14, for a total transaction of $900,630.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, September 17th, Xiaobin Wu sold 500 shares of BeiGene stock. The shares were sold at an average price of $200.00, for a total value of $100,000.00.
• On Tuesday, September 3rd, Xiaobin Wu sold 5,556 shares of BeiGene stock. The shares were sold at an average price of $189.65, for a total value of $1,053,695.40.
• On Monday, June 24th, Xiaobin Wu sold 1,459 shares of BeiGene stock. The stock was sold at an average price of $159.79, for a total transaction of $233,133.61.

BeiGene Stock Performance

BeiGene stock opened at $201.99 on Friday. The firm has a market capitalization of $19.57 billion, a P/E ratio of -26.68 and a beta of 0.61. The company’s 50-day moving average is $182.24 and its 200 day moving average is $164.45. BeiGene, Ltd. has a 1-year low of $126.97 and a 1-year high of $215.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75.

BeiGene (NASDAQ:BGNE) last issued its earnings results on Wednesday, August 7th. The company reported ($1.15) EPS for the quarter, topping analysts’ consensus estimates of ($2.27) by $1.12. The business had revenue of $929.20 million for the quarter, compared to analyst estimates of $810.34 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The company’s quarterly revenue was up 56.1% compared to the same quarter last year. During the same period last year, the company posted ($3.64) earnings per share. Research analysts forecast that BeiGene, Ltd. will post -5.13 EPS for the current year.

Hedge Funds Weigh In On BeiGene

A number of institutional investors have recently modified their holdings of BGNE. Headlands Technologies LLC bought a new position in shares of BeiGene during the first quarter valued at approximately $50,000. Benjamin F. Edwards & Company Inc. boosted its stake in shares of BeiGene by 51.5% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock valued at $128,000 after purchasing an additional 279 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of BeiGene during the fourth quarter valued at approximately $183,000. Dynamic Technology Lab Private Ltd bought a new position in shares of BeiGene during the fourth quarter valued at approximately $215,000. Finally, Acadian Asset Management LLC boosted its stake in shares of BeiGene by 204.1% during the first quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock valued at $197,000 after purchasing an additional 849 shares in the last quarter. 48.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on BGNE shares. JMP Securities assumed coverage on shares of BeiGene in a report on Wednesday. They issued a “market outperform” rating and a $288.00 price objective for the company. Bank of America reduced their price target on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research report on Tuesday, July 9th. JPMorgan Chase & Co. lifted their target price on shares of BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Finally, Citigroup lifted their target price on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $241.21.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.